Pasithea Therapeutics Corp (KTTA) Price & Analysis

Compare

146 Followers

KTTA Stock Chart & Stats

$0.92

-$0.19(-6.35%)

At close: Jan 08 4:00 PM EST

$0.92

-$0.19(-6.35%)

Day’s Range― - ―

52-Week Range$0.28 - $3.85

Previous CloseN/A

Volume25.24K

Average Volume (3M)98.68K

Market Cap

$21.27M

Enterprise ValueN/A

Total Cash (Recent Filing)$4.12M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta4.09

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding23,091,063

10 Day Avg. Volume100,274

30 Day Avg. Volume98,683

Financial Highlights & Ratios

PEG Ratio-0.79

Price to Book (P/B)0.23

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$3.00

Price Target Upside226.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical ReadoutsAnalyst notes that initial safety and efficacy data from the first cohorts in the Phase 1 NF1-PN study could act as a meaningful valuation catalyst by validating PAS-004's clinical profile.

Drug Design AdvantageThe macrocyclic design of PAS-004 is intended to improve target binding, selectivity, and oral bioavailability, which may translate into better tolerability and competitive differentiation.

Market OpportunityPasithea’s pipeline could provide access to a multi-billion-dollar market across multiple indications, offering meaningful revenue upside if PAS-004 demonstrates clinical benefit.

Bears Say

Clinical Development RiskHigh clinical burden and unmet need in NF1 tumors raises the efficacy and durability expectations for new treatments, increasing the risk that PAS-004 might not meet critical trial endpoints.

Commercial Adoption UncertaintyComplex disease management in NF1 tumors could limit rapid commercial uptake unless PAS-004 shows clear superiority over existing standards of care.

Safety And Tolerability RiskThe emphasis on early and effective intervention in NF1 increases the importance of a clean safety profile, so trial adverse events could materially delay or derail regulatory progress.

Pasithea Therapeutics Corp News

Pasithea Therapeutics Regains Nasdaq Compliance

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an announcement. Pasithea Therapeutics Corp. announced that it has regained...

28d ago

KTTA

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics (KTTA) with a Buy rating and $3 price...

1M ago

KTTA

3 Penny Stocks to Watch Now, 12/2/25

Pasithea Therapeutics ($KTTA), Aditxt ($ADTX), and HeartBeam ($BEAT) are the 3 Penny Stocks to watch on December 2, 2025, based...

1M ago

ADTX

BEAM

Pasithea Therapeutics Completes $60M Public Offering

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. On November 28, 2025, Pasithea Therapeutics Corp announced...

1M ago

KTTA

Pasithea Therapeutics prices 80M shares at 75c in public offering

Pasithea Therapeutics (KTTA) announced the pricing of a public offering of 80,000,000 shares of the Company’s common stock...

2M ago

KTTA

3 Penny Stocks to Watch Now, 11/27/25

Zynex Inc., Amber International Holding, and Pasithea Therapeutics are the 3 Penny Stocks to watch on November 27, 2025, based...

2M ago

AMBR

KTTA

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. Pasithea Therapeutics announced positive interim Phase 1 data...

2M ago

KTTA

Pasithea Therapeutics announces $1M award by ALS Association

Pasithea Therapeutics (KTTA) announced that the ALS Association has awarded a Hoffman ALS Clinical Trial Award grant worth...

2M ago

KTTA

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

Pasithea Therapeutics (KTTA) announced safety, PK and PD data from Cohort 7 in its ongoing first-in-human trial evaluating...

2M ago

KTTA

Pasithea says tablet PK exposure increases proprtionally with dose increase

Pasithea Therapeutics (KTTA) announced tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients...

2M ago

KTTA

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Earnings reports, acquisitions, and other news are leading the top stock market stories for Friday. ...

2M ago

Why Is Pasithea Therapeutics Stock (KTTA) Down Today?

Pasithea Therapeutics stock fell after the company posted poor interim clinical trial data. ...

2M ago

KTTA

Pasithea Therapeutics announces interim data from PAS-004 trial

Pasithea Therapeutics (KTTA) announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with...

2M ago

KTTA

Pasithea announces activation of trial site at UAB for study of PAS-004

Pasithea Therapeutics (KTTA) announced activation of a new U.S. clinical trial site at the University of Alabama at...

2M ago

KTTA

KTTA FAQ

What was Pasithea Therapeutics Corp’s price range in the past 12 months?

Pasithea Therapeutics Corp lowest stock price was $0.28 and its highest was $3.85 in the past 12 months.

What is Pasithea Therapeutics Corp’s market cap?

Pasithea Therapeutics Corp’s market cap is $21.27M.

When is Pasithea Therapeutics Corp’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pasithea Therapeutics Corp’s earnings last quarter?

Currently, no data Available

Is Pasithea Therapeutics Corp overvalued?

According to Wall Street analysts Pasithea Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pasithea Therapeutics Corp pay dividends?

Pasithea Therapeutics Corp does not currently pay dividends.

What is Pasithea Therapeutics Corp’s EPS estimate?

Pasithea Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pasithea Therapeutics Corp have?

Pasithea Therapeutics Corp has 23,091,063 shares outstanding.

What happened to Pasithea Therapeutics Corp’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pasithea Therapeutics Corp?

Currently, no hedge funds are holding shares in KTTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Pasithea Therapeutics Corp (KTTA) Earnings & Revenues

Historic Earnings Reports

KTTA Stock 12 Month Forecast

Average Price Target

$3.00

▲(226.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","34":"$34","51":"$51","68":"$68"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,17,34,51,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Oct<br/>2021","9":"Dec<br/>2021","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":67,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":57.4,"date":1633046400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":51.4,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66,"date":1638316800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >